Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection

Transplantation

Volumn 68, Issue 11, 1999, Pages 1632-1637

  Friend, P J ^a   Hale, G ^b   Chatenoud, L ^c   Rebello, P ^b   Bradley, J ^a   Thiru, S ^a   Phillips, J M ^a   Waldmann, H ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CHLORPHENIRAMINE; COMPLEMENT; CYCLOSPORIN A; FC RECEPTOR; GAMMA INTERFERON; HYDROCORTISONE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN HEAVY CHAIN; INTERLEUKIN 10; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY CD3; OKT 3; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

AMINO ACID SUBSTITUTION; ARTICLE; BIOENGINEERING; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPLEMENT FIXATION; CYTOKINE RELEASE; DRUG POTENCY; DRUG RECEPTOR BINDING; FEVER; FLU LIKE SYNDROME; GLYCOSYLATION; HEADACHE; HUMAN; HUMAN TISSUE; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; VOMITING;

EID: 0033572786     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199912150-00005     Document Type: Article

References (29)

1. Waldmann H, Cobbold S. How do monoclonal antibodies induce tolerance? A role for infectious tolerance? Annu Rev Immunol 1998; 16: 619.
2. Chatenoud L, Thervett E, Primo J, Bach JF. Anti-CD3 antibody induces long-term remission of overt autoimmunity in non-obese diabetic mice. Proc Natl Acad Sci USA 1994; 91: 123.
3. Ortho Multicenter Transplant Study Group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 1985; 313: 337.
4. Goldstein G. An overview of ORTHOCLONE OKT3. Transplant Proc 1986; 18: 927.
5. Grino JM, Castelao AM, Seron D, et al. Anti-lymphocyte globulin versus OKT3 induction therapy in cadaveric renal transplantation: a prospective randomised study. Am J Kidney Dis 1992; 20: 603.
6. Opelz G. Efficacy of rejection prophylaxis with OKT3 in renal transplantation. Transplantation 1995; 60: 1220.
7. Abramowicz D, Sehandere L, Goldman M. Release of tumor necrosis factor, interleukin-2 and gamma interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 1989; 47: 606.
8. Chatenoud L, Ferran C, Legendre C, et al. In vivo cell activation following OKT3 administration: systemic cytokine release and modulation by corticosteroids. Transplantation 1990; 49: 697.
9. Chatenoud L, Baudrihaye MF, Chkoff N, Kreis H, Goldstein G, Bach JF. Restriction of the human in vivo immune response against the mouse monoclonal antibody OKT3. J Immunol 1986; 137: 830.
10. Jaffers GJ, Fuller TC, Cosimi AB, Russell PS, Winn HJ, Colvin RB. Monoclonal antibody therapy: anti-idiotypic and non-antiidiotypic antibodies to OKT3 arising from intense immunosuppression. Transplantation 1986; 41: 572.
11. Van Wauwe JP, De Mey JR, Goosens JG. OKT3: a monoclonal anti-human T-lymphocyte antibody with potent mitogenic properties. J Immunol 1980; 124: 2708.
12. 2 fragments are immunosuppressive in vivo without evoking either the strong humoral response or morbidity associated with the whole mAb. Transplantation 1990; 49: 1117.
13. Alegre ML, Vandenabeele P, Depierreux M, et al. Cytokine release syndrome induced by the 145-2C11 anti-CD3 monoclonal antibody in mice: prevention by high doses of methyl prednisolone. J Immunol 1991; 146: 1184.
14. Norman D, Chatenoud L, Cohen D, Goldmann M, Shield C. Consensus statement regarding OKT3-induced cytokine release syndrome and human anti-mouse antibodies. Transplant Proc 1992; 25: 89.
15. Cobbold SP, Waldmann H. Therapeutic potential of monovalent monoclonal antibodies. Nature 1984; 308: 460.
16. Clark M, Bindon C, Dyer M, et al. The improved lytic function and in vivo efficacy of monovalent monoclonal CD3 antibodies. Eur J Immunol 1989; 19: 381.
17. Abbs IC, Clark M, Waldmann H, Chatenoud L, Koffman CG, Sacks SH. Sparing of first dose effect of monovalent anti-CD3 antibody used in allograft rejection is associated with a diminished release of pro-inflammatory cytokines. J Ther Immunol 1994; 6: 325.
18. Routledge EG, Lloyd I, Gorman S, Clark M, Waldmann H. A humanized monovalent CD3 antibody which can activate homologous complement. Eur J Immunol 1991; 21: 2717.
19. Bolt S, Routledge E, Lloyd I, et al. The generation of a humanised, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur J Immunol 1993; 23: 403.
20. Tao MH, Morrison SL. Studies on aglycosylated chimeric mouse human IgG: role of carbohydrate in the structure and effector functions mediated by human IgG constant region. J Immunol 1989; 143: 2595.
21. Alegre ML, Peterson LJ, Xu D, et al. A non-activating CD3 monoclonal antibody retains immunosuppressive properties in vivo. Transplantation 1994; 57: 1537.
22. Solez K, Axelsen RA, Benediktsson H, et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993; 44(2): 411.
23. Thistlethwaite JR, Cosimi AB, Delmonico FL, et al. Evolving use of OKT3 monoclonal antibody for treatment of allograft rejection. Transplantation 1984; 288: 695.
24. Cobbold SP, Rebello PRUB, Davies Hff, Friend PJ, Clark MR. A simple method for measuring patient anti-globulin responses against isotypic or idiotypic determinants. J Immunol Methods 1990; 127: 19.
25. Knight RJ, Kurrie R, McLain J, et al. Clinical evaluation of induction immunosuppression with a murine IgG2b monoclonal antibody (BMA 031) directed toward the human alph/beta-T-cell receptor. Transplantation 1994; 57: 1581.
26. Chatenoud L, Legendre C, Kurrle R, Kreis H, Bach JF. Absence of clinical symptoms following the first injection of anti-T cell receptor monoclonal antibody (BMA 031) despite isolated TNF release. Transplantation 1993; 55: 443.
27. Smith JA, Tso JY, Clark MR, Cole MS, Bluestone JA. Non-mitogenic anti-CD3 monoclonal antibody delivers a partial T cell receptor signal and induces clonal anergy. J Exp Med 1997; 185: 1413.
28. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with monoclonal antibody OKT3 in cardiac-transplant patients. N Engl J Med 1990; 323: 1723.
29. Routledge E, Waldmann H. The effect of aglycosylation on the immunogenicity of a humanized therapeutic CD3 antibody. Transplantation 1995; 60: 847.